Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M26.6Revenue $M6.6Net Margin (%)--Altman Z-Score-12.1
Enterprise Value $M-54.7EPS $-0.7Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)--Higher ROA y-yY
Price/Book0.410-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-79.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-121.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M138ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SNTA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNTAFirst Eagle Investment 2012-06-30 Sold Out -0.0035%$3.68 - $7.82
($4.69)
$ 0.19-96%Sold Out0
SNTAFirst Eagle Investment 2012-03-31 Buy $4.22 - $5.66
($4.49)
$ 0.19-96%New holding200,000
SNTAMichael Price 2011-06-30 Sold Out -0.1%$4.45 - $6.23
($5.37)
$ 0.19-96%Sold Out0
SNTAMichael Price 2010-06-30 Buy 0.07%$2.67 - $4.79
($3.62)
$ 0.19-95%New holding118,058
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNTA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SNTA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Gollust Keith RDirector 2015-12-14Sell600,000$0.35-45.71view
Gollust Keith RDirector 2015-12-09Sell745,892$0.38-50view
Kovner BruceDirector, 10% Owner 2015-12-08Sell1,523,346$0.37-48.65view
Kovner BruceDirector, 10% Owner 2015-12-03Sell1,430,753$0.43-55.81view
Kovner BruceDirector, 10% Owner 2015-11-30Sell3,078,820$0.48-60.42view
Kovner BruceDirector, 10% Owner 2015-11-24Sell1,173,582$0.44-56.82view
Kovner BruceDirector, 10% Owner 2015-11-20Sell1,513,088$0.49-61.22view
Kovner BruceDirector, 10% Owner 2015-11-17Sell1,223,936$0.43-55.81view
Gollust Keith RDirector 2015-11-17Sell100,000$0.41-53.66view
Kovner BruceDirector, 10% Owner 2015-11-12Sell5,436,673$0.55-65.45view

Quarterly/Annual Reports about SNTA:

    News about SNTA:

    Articles On GuruFocus.com
    Insiders Sell Twitter and Cannabis Science, Buy DSW and WhiteHorse Dec 04 2015 
    Stocks Both Gurus and Company Insiders Are Buying Jun 18 2015 
    Insider Buys: FULL, FMI and SNTA Apr 10 2015 
    Weekly 3-Year Low Highlights: NSR, ELRC, PLPC, SNTA Feb 16 2015 
    5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
    5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Servic Jan 11 2015 
    5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

    More From Other Websites
    ​Two local biotechs that are now valued lower than their bank accounts Feb 12 2016
    This Company is Up +400% in a Month Jan 07 2016
    4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume Dec 15 2015
    Here is What Hedge Funds Think About United Community Financial Corp (UCFC) Dec 13 2015
    SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Dec 09 2015
    SYNTA PHARMACEUTICALS CORP Financials Dec 08 2015
    Is Synta Pharmaceuticals Corp. (SNTA) A Good Stock To Buy? Nov 22 2015
    Synta Q3 Loss Narrower than Expected, to Cut Jobs by 60% Nov 06 2015
    Synta Reports Third Quarter 2015 Financial Results Nov 05 2015
    SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Nov 05 2015
    Synta Reports Third Quarter 2015 Financial Results Nov 05 2015
    Synta (SNTA) Q3 Earnings Preview: What's in the Cards? Nov 03 2015
    8 BioPharma Movers That Cannot Be Ignored Oct 24 2015
    Synta Falls, Stops Ganetespib Late-Stage Lung Cancer Study Oct 23 2015
    SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 22 2015
    Synta shares plunge as company gives up on trial of lead drug in lung cancer Oct 21 2015
    Ergomed Co-Development Partner News Oct 21 2015
    Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer Oct 20 2015
    SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 16 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK